After years of trying to catch up with the competition, Boston Scientific is moving on. The company is no longer seeking approval from the FDA or any other regulatory agencies for these devices, and all global sales have been discontinued.

"As cannabis legalization increases, it is crucial to understand the public health and clinical implications of marijuana use," researchers wrote in JAMA Cardiology.

Indian medtech company Meril Life Sciences has been manufacturing its Myval TAVR valves for years, but FDA approval has remained out of reach. These latest data represent a one-year update of the multicenter LANDMARK clinical trial.

"The lead protection we wear is causing a lot of damage," SCAI President Srihari S. Naidu, MD, a veteran interventional cardiologist, explained in an interview.

To be exact, the average weight time for a cardiologist appointment in U.S. cities is 32.7 days. This is a 23% increase compared to 2022 and a 74% increase compared to 2004.

Rishi Wadhera, MD, MPP, MPhil, a cardiologist who also specializes in healthcare policy, spoke to Cardiovascular Business about the good, the bad and the unknown when it comes to private equity's role in cardiology.

The new Topaz TTVR system was associated with the consistent elimination of tricuspid regurgitation. In addition, none of the first 20 patients treated with the device required a permanent pacemaker as a result of the procedure.

The self-expanding valve, which gained CE mark approval back in 2020, is available in multiple sizes and can be fully retrieved and repositioned as it is implanted.

The Prevail DCB has been cleared to use in dozens of countries around the globe, but it has not yet been approved by the FDA.

Cuffless BP measurements could potentially provide significant value for clinicians and patients alike. It is still too early, however, for these technologies to be used in a clinical setting; too many unanswered questions remain.